NYU Langone Health in the News—June 26, 2024
At NYU Langone, our experts are frequently featured in various media outlets to share their skills and knowledge. See the stories from June 26, 2024.
NYU Langone Research Leads to Bladder Cancer Drug Approval
NYU Langone research leads to FDA approval of new drug, pembrolizumab, to treat advanced bladder cancer.
Randomized Testing Helps Create a Learning Health System
A program at NYU Langone Health uses rapid-cycle, randomized testing to assess the effectiveness of patient-focused programs.
Shaping Healthcare in New York City’s Most Populous Borough
NYU Langone plans to invest more than $500 million in NYU Langone Hospital—Brooklyn over the next 5 years.
Study Finds Low Risk Stopping HCQ in Older Lupus Patients
NYU Langone’s Dr. Jill Buyon and Dr. Peter Izmirly find low risk when stopping HCQ to avoid eye-damaging toxicity for older lupus patients.
Study Shows Alternate Origins of Alzheimer’s Disease Plaques
NYU Langone study sources neuronal damage in Alzheimer’s disease to problems inside brain cells’ lysosomes, where amyloid beta first appears.
Tool Gauges Sexual Health in Couples Facing Prostate Cancer
NYU Langone researchers developed a survey to assess sexual health challenges in the female partners of patients who have prostate cancer.
Vital Genetic Mechanism Detailed
A study led by NYU Langone Researchers revealed how a particular type of “jumping” gene came to make up 20 percent of human DNA.
2023 Grant Awards | NYU Langone Health
Several of NYU Langone Judith and Steward Colton Center pilot projects received grant funding in 2023.
About the Center for Cognitive Neurology | NYU Langone Health
NYU Langone’s Center for Cognitive Neurology has been treating and researching Alzheimer’s disease for more than three decades.